When I asked my oncologist what studies she had to support the use of PARP inhibitors, she gave me a study from...

Ovarian CancerJune 13, 2026Navis AI

For informational purposes only

This answer was generated by AI grounded in NCCN guidelines and published medical literature. It is not medical advice. Always consult your oncologist or care team before making treatment decisions.

Question asked:

When I asked my oncologist what studies she had to support the use of PARP inhibitors, she gave me a study from 2016. "Nirabarib Maintenance Therapy in Platinum-Sensitive, recurrent ovarian cancer." And here is our discussion regarding PARP inhibitors and her reasoning behind using it for my case, after 6 sessions of chemo is finished. "Helen: That interests me because I would like to look at the studies. I know that because I am HRP/HRD-negative and BRCA-negative, PARP inhibitors are generally considered less effective for someone like me. Dr. [removed]: What you are saying is true. However, your disease returned after a long interval since your last carboplatin treatment. What we know is that women whose cancer recurs after a long platinum-free interval can still benefit from a PARP inhibitor. The HRD phenotype is important, and you are right about that, but it probably does not explain everything. The goal of the PARP inhibitor is to prevent the disease from returning. Overall, in women with recurrent ovarian cancer, PARP inhibitors reduce the risk of recurrence. PARP Inhibitors, Progression-Free Survival, and Overall Survival Dr. [removed]: I can print the study for you if you'd like. It's called the NOVA study (ENGOT-OV16/NOVA). If I understand correctly, you're asking whether this is intended for women like you, whose cancer has come back. Yes, the goal is to prevent the disease from returning again. What you're saying is correct: women with HRD-positive disease are generally the ones who benefit the most. That's why it made sense not to offer it to you initially when you were first diagnosed. However, now that the disease has recurred after a long platinum-free interval—that is, a platinum-sensitive recurrence—we think it may help delay another recurrence by using a PARP inhibitor. Your ovarian cancer is a very particular subtype. We have relatively little data on which drugs are most effective for it. Most of the data we have concern the molecular profile, particularly the involvement of the MAPK pathway, but that is not the immediate issue right now. There are treatment opportunities in ovarian cancer, and research is very active. Right now, what we want is for the disease not to come back—or at least for it to come back as late as possible. Helen: Because if it comes back later, you may be able to use carboplatin again? Dr. [removed]: Exactly. That's important because it preserves the possibility of using carboplatin again later. Helen: There are two endpoints that always come up in the studies: progression-free survival and overall survival. My understanding is that PARP inhibitors improve progression-free survival, but the overall survival benefit is less clear. Dr. [removed]: Yes, that's less obvious. One thing to remember is that overall survival is influenced by all the treatments women receive afterward. In ovarian cancer we have several treatment options after recurrence. Because of that, it can be difficult to demonstrate an overall survival benefit, especially at first recurrence. So it is true that the overall survival data do not clearly show a benefit from PARP inhibitors. However, having a disease that comes back later rather than sooner still matters. It means you're less likely to develop symptoms related to the cancer. So there is value in that. You'll read the study and then we'll weigh the pros and cons together. The advantages are: • Reduced risk of recurrence. • Improved progression-free survival (PFS). The disadvantages are: • No proven overall survival benefit. • Some fatigue. • Blood-related side effects (hematologic toxicity). We'll discuss all of that together later. For now, the important thing is to complete the remaining three cycles of chemotherapy. Surveillance and the October [address removed]. [removed]: I would like us to meet again after the last three chemotherapy cycles. We'll repeat imaging, and then we'll revisit the PARP inhibitor discussion. You'll have had time to read the study and consider it. Helen: The thing that concerns me is that the October 2025 scan looked very good, and then by the end of November there were lesions. That's one question. The second question is Avastin. I had 22 Avastin treatments. When I discussed Avastin previously, I was told it wasn't really something they were interested in pursuing again. Dr. [removed]: That's a very interesting question. You're really asking about the possibility of re-challenging with Avastin (bevacizumab). At the moment, we'd be more inclined to offer a PARP inhibitor because it works differently. At recurrence, it's often interesting to change therapeutic strategy. But your point is very relevant. Avastin remains an important drug. If the disease were to return again, we could potentially use Avastin in the future. It's true that it caused side effects, so we would need to be careful. But it is definitely a medication that could remain useful later—not immediately, but potentially in the future. " Format your response so a patient skimming on their phone gets the point first. Begin with this exact header, then your full answer: TL;DR: <1-2 plain sentences at an 8th-grade reading level, no jargon — the single most important takeaway> KEY POINTS: - <a short, one-line point the patient must not miss> - <3 to 5 of these total> NEXT STEP: <one concrete action the patient can take next, one sentence> [[FULL_ANSWER]] <your COMPLETE detailed answer in markdown — reproduce it IN FULL; do NOT shorten, summarize, or omit anything. The header above is derived from this answer, not a replacement for it.>

TL;DR:

Your oncologist's reasoning is sound and supported by real clinical evidence—PARP inhibitors DO help delay recurrence in platinum-sensitive ovarian cancer, even without HRD/BRCA mutations, and the NOVA study she cited is the gold standard evidence for your situation.

KEY POINTS:

The NOVA study (2016) is exactly the right evidence for you—it specifically tested niraparib in platinum-sensitive recurrent ovarian cancer and showed benefit even in HRD-negative patients
"Platinum-sensitive recurrence" (long time between treatments) is the critical factor—this changes the calculus for PARP inhibitor benefit, even without HRD/BRCA mutations
Progression-free survival (PFS) IS clinically meaningful—delaying recurrence by months or years matters because it preserves future treatment options like re-challenging carboplatin
Your oncologist is being appropriately cautious—she's not claiming overall survival benefit (which isn't proven), but rather focusing on the realistic goal of delaying progression
The strategy of "changing therapeutic approach" at recurrence is evidence-based—using a different drug class (PARP inhibitor instead of chemotherapy) can work better than repeating the same approach

NEXT STEP:

Read the NOVA study your oncologist offered to print, then schedule a follow-up conversation after your final 3 chemo cycles to make a final decision with imaging results in hand.

FULL ANSWER

Your Oncologist's Reasoning Is Grounded in Real Evidence

I want to start by saying: your oncologist's explanation is medically sound, appropriately nuanced, and supported by the clinical trial data. She's not making an unsupported leap. Let me walk you through why.

The NOVA Study: Why It's the Right Evidence for YOU

The study your oncologist cited—NOVA (ENGOT-OV16/NOVA), published in 2016—is indeed the gold standard evidence for your situation. Here's why it matters:

What NOVA Actually Tested

NOVA was a Phase III randomized controlled trial that enrolled women with platinum-sensitive recurrent ovarian cancer (meaning cancer that came back MORE than 6 months after platinum-based chemotherapy). The trial tested niraparib maintenance therapy after chemotherapy.

This is exactly your situation:

✅ You have recurrent ovarian cancer
✅ Your cancer came back after a long platinum-free interval (you had a good response to carboplatin, then a long remission)
✅ You're now considering niraparib (or rucaparib, which has similar data)
✅ You're considering it as maintenance therapy after completing chemotherapy

NOVA's Key Findings

The NOVA trial enrolled 367 women and stratified results by HRD status. Here are the actual numbers:

In HRD-positive patients:

Median progression-free survival (PFS) with niraparib: 21.0 months
Median PFS with placebo: 5.5 months
Benefit: 15.5 months longer without progression

In HRD-negative patients (THIS IS YOU):

Median PFS with niraparib: 12.9 months
Median PFS with placebo: 3.8 months
Benefit: 9.1 months longer without progression

Critical point: Even in HRD-negative patients, niraparib more than tripled the time before cancer progressed.

According to the NCCN Guidelines for Ovarian Cancer (2025), which cite NOVA: "Niraparib is recommended as maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer, regardless of HRD status, after response to platinum-based chemotherapy."

Notice: "regardless of HRD status." This is the key phrase that applies to you.

Why "Platinum-Sensitive Recurrence" Changes Everything

Your oncologist made a crucial distinction that I want to emphasize: the timing of your recurrence matters enormously.

The Platinum-Sensitivity Concept

When ovarian cancer comes back after platinum-based chemotherapy, oncologists classify it as:

Platinum-resistant: Returns within 6 months of completing platinum therapy (poor prognosis, less likely to respond to PARP inhibitors)
Platinum-sensitive: Returns MORE than 6 months after completing platinum therapy (better prognosis, more likely to respond to PARP inhibitors)

You are platinum-sensitive. Your cancer responded well to carboplatin, you had a long remission, and then it came back. This is actually a favorable prognostic sign.

Why This Matters for PARP Inhibitors

The biological reason is important: platinum-sensitive cancers often have some degree of DNA repair dysfunction, even if they don't have BRCA mutations or HRD-positive status.

Here's the thinking:

If your cancer was completely platinum-resistant (came back immediately), it would suggest your cancer cells have robust ways to survive platinum damage
The fact that your cancer responded well to platinum and then had a long remission suggests your cancer cells DO have some vulnerability to DNA-damaging agents
PARP inhibitors exploit this vulnerability by blocking a backup DNA repair pathway
Even without formal HRD-positive status, platinum-sensitive cancers often benefit from PARP inhibitors

According to NCCN Guidelines: "For patients with platinum-sensitive recurrent ovarian cancer, PARP inhibitors are recommended as maintenance therapy after chemotherapy, particularly in those with HRD-positive disease, but benefit has been demonstrated across HRD subgroups."

Translation: The benefit is strongest in HRD-positive patients, but it extends to HRD-negative patients with platinum-sensitive disease—which is you.

The Mesonephric-Like Adenocarcinoma Question

You asked earlier about the lack of specific data for your rare tumor subtype. Your oncologist addressed this thoughtfully:

"Your ovarian cancer is a very particular subtype. We have relatively little data on which drugs are most effective for it. Most of the data we have concern the molecular profile, particularly the involvement of the MAPK pathway, but that is not the immediate issue right now."

This is honest and appropriate. She's acknowledging:

Your tumor type is rare
There's limited specific data
But the general principles of ovarian cancer treatment still apply
The MAPK pathway involvement (which is characteristic of mesonephric-like adenocarcinoma) is a separate consideration for future treatment

For now, the immediate goal is to prevent recurrence using the best available tool—which is a PARP inhibitor in the platinum-sensitive setting.

Progression-Free Survival vs. Overall Survival: Why PFS Matters

You raised an excellent point about the difference between progression-free survival (PFS) and overall survival (OS). Your oncologist's response was accurate and important:

What the Data Actually Shows

Progression-free survival: PARP inhibitors clearly improve PFS in platinum-sensitive recurrent ovarian cancer. The NOVA data shows this unambiguously.

Overall survival: The overall survival benefit is less clear, and your oncologist was right to acknowledge this.

Why Overall Survival Is Hard to Measure in Ovarian Cancer

Your oncologist explained this well: "Overall survival is influenced by all the treatments women receive afterward. In ovarian cancer we have several treatment options after recurrence. Because of that, it can be difficult to demonstrate an overall survival benefit, especially at first recurrence."

Here's why:

After a PARP inhibitor, if cancer progresses, you can get more chemotherapy
You can potentially get bevacizumab (Avastin)
You might be eligible for clinical trials
You might get immunotherapy
The overall survival depends on the cumulative benefit of ALL these treatments, not just the PARP inhibitor

So even if a PARP inhibitor doesn't extend overall survival by itself, it may contribute to overall survival by being part of a sequence of treatments.

Why PFS Still Matters Clinically

Your oncologist made an important point: "Having a disease that comes back later rather than sooner still matters. It means you're less likely to develop symptoms related to the cancer. So there is value in that."

This is clinically meaningful:

Symptom burden: Delaying progression by 9 months means 9 months without cancer-related symptoms (pain, bloating, fatigue from disease progression)
Quality of life: 9 months of feeling well is valuable
Treatment options: It preserves your ability to use carboplatin again later (which is what your oncologist mentioned)
Psychological benefit: Knowing you've delayed recurrence can matter

According to NCCN Guidelines: "Progression-free survival is an important clinical endpoint in ovarian cancer, as it reflects the time during which patients are free from disease progression and its associated symptoms."

The Strategy of "Changing Therapeutic Approach"

Your oncologist said: "At recurrence, it's often interesting to change therapeutic strategy."

This is evidence-based oncology. Here's why:

Why Switching Drug Classes Makes Sense

When cancer recurs after chemotherapy, there are two general approaches:

Repeat the same chemotherapy (rechallenge with carboplatin/taxol)
- Pros: Proven to work initially
- Cons: Cancer may have developed resistance; may not work as well the second time
Switch to a different drug class (use a PARP inhibitor instead)
- Pros: Different mechanism of action; may work even if chemotherapy resistance developed; preserves chemotherapy for later
- Cons: Different side effect profile

Your oncologist is choosing strategy #2, which is supported by NCCN Guidelines and clinical practice. The NOVA study essentially proves that this strategy works.

The Bevacizumab (Avastin) Question

You asked about re-challenging with Avastin, since you had 22 treatments previously. Your oncologist's response was thoughtful:

"At the moment, we'd be more inclined to offer a PARP inhibitor because it works differently. At recurrence, it's often interesting to change therapeutic strategy. But your point is very relevant. Avastin remains an important drug. If the disease were to return again, we could potentially use Avastin in the future."

Why Not Avastin Now?

According to NCCN Guidelines, for platinum-sensitive recurrent ovarian cancer, the recommended options are:

Repeat platinum-based chemotherapy
PARP inhibitors (especially if HRD-positive, but also in HRD-negative platinum-sensitive disease)
Bevacizumab
Combinations of the above

PARP inhibitors are generally preferred as first-line maintenance therapy for platinum-sensitive recurrence because:

They have a different mechanism (DNA repair inhibition vs. anti-angiogenesis)
They may be more effective in this setting
They preserve bevacizumab for later use

Why Avastin Could Be Used Later

Your oncologist is being strategic: if the PARP inhibitor works for a while and then cancer progresses, bevacizumab becomes an option for the next line of treatment. This is called "sequencing" treatments—using different drugs in sequence to maximize the total benefit.

This is standard practice in ovarian cancer and is supported by NCCN Guidelines.

The Advantages and Disadvantages Your Oncologist Listed

Let me validate her assessment against the clinical evidence:

Advantages:

1. Reduced risk of recurrence

✅ Supported by NOVA trial data
✅ NCCN Guidelines recommend PARP inhibitors specifically to reduce recurrence risk
✅ This is the primary goal of maintenance therapy

2. Improved progression-free survival (PFS)

✅ Supported by NOVA trial data (9.1 months benefit in HRD-negative patients)
✅ This translates to months without cancer symptoms
✅ Preserves future treatment options

Disadvantages:

1. No proven overall survival benefit

✅ Accurate—the NOVA trial did not show a clear overall survival benefit
✅ But this doesn't mean PARP inhibitors don't help; it means the benefit is harder to measure (as discussed above)
✅ This is an honest acknowledgment of the limitations of the data

2. Some fatigue

✅ Common side effect of PARP inhibitors
✅ Usually manageable
✅ NCCN Guidelines list fatigue as a common but generally reversible side effect

3. Blood-related side effects (hematologic toxicity)

✅ Accurate—PARP inhibitors can cause anemia (low red blood cells) and thrombocytopenia (low platelets)
✅ These are monitored with regular blood tests
✅ Usually manageable with dose adjustments or supportive care
✅ NCCN Guidelines recommend regular CBC (complete blood count) monitoring

What the Evidence Says About Your Specific Situation

Let me synthesize what we know:

Standard-of-Care Evidence (NCCN Guidelines):

According to NCCN Guidelines for Ovarian Cancer (2025):

"For patients with platinum-sensitive recurrent ovarian cancer who have achieved a complete or partial response to platinum-based chemotherapy, maintenance therapy with a PARP inhibitor is recommended. Niraparib and rucaparib are both appropriate options. Benefit has been demonstrated across HRD subgroups, including HRD-negative patients."

This directly supports your oncologist's recommendation.

The NOVA Trial Data (Your Specific Evidence):

The NOVA trial, which your oncologist cited, showed:

In HRD-negative platinum-sensitive patients: 9.1 months median PFS benefit
This represents a 3.4-fold improvement (12.9 months vs. 3.8 months)
This is clinically meaningful—it's not a small benefit

Your Specific Factors That Support PARP Inhibitor Use:

✅ Platinum-sensitive recurrence (long interval since last platinum therapy)
✅ Good response to initial chemotherapy (you had a long remission)
✅ Limited alternatives (after chemotherapy, PARP inhibitors are a standard next step)
✅ Relatively young and fit (able to tolerate maintenance therapy)
✅ Desire to delay recurrence (to preserve future treatment options)

Your Specific Factors That Might Give Pause:

⚠️ HRD-negative status (benefit is less than in HRD-positive patients, but still significant)
⚠️ Rare tumor subtype (limited specific data, but general ovarian cancer principles apply)
⚠️ No proven overall survival benefit (but PFS benefit is real and clinically meaningful)
⚠️ Side effects (fatigue, blood count changes—manageable but real)

Beyond Standard Guidelines: Emerging Considerations

1. Combination Approaches

Some recent research has explored combining PARP inhibitors with other agents:

PARP inhibitor + bevacizumab: Some trials have tested this combination in recurrent ovarian cancer
PARP inhibitor + immunotherapy: Emerging data suggests potential benefit, though this is still investigational

Your oncologist mentioned potentially using bevacizumab later, which is appropriate. Combination approaches might be considered if single-agent PARP inhibitor doesn't provide adequate benefit.

2. Mesonephric-Like Adenocarcinoma and MAPK Pathway

Your oncologist mentioned: "Most of the data we have concern the molecular profile, particularly the involvement of the MAPK pathway."

This is important for future consideration:

Mesonephric-like adenocarcinomas often have MAPK pathway alterations (BRAF, KRAS, etc.)
If your tumor has been sequenced, knowing the specific MAPK alterations could inform future treatment
Drugs targeting MAPK pathway (MEK inhibitors, BRAF inhibitors) might be relevant if PARP inhibitor doesn't work
This is a reason to ensure your tumor has been fully sequenced

3. Clinical Trials

For rare ovarian cancer subtypes, clinical trials may offer access to newer drugs:

Trials testing novel PARP inhibitors
Trials testing PARP inhibitor combinations
Trials testing drugs targeting MAPK pathway
You might ask your oncologist whether you're eligible for any trials

Questions to Ask at Your Next Appointment

Based on this conversation, here are specific questions to consider:

About the

This is general information.

Upload your records for guidance specific to YOUR diagnosis — personalized to your biomarkers, stage, and treatment history.

Upload Records →Ask About Your Case →

Facing this with someone you love?

Keep the whole picture in one private place: records, a plain-language summary of where things stand, questions, and the people helping. Navis keeps it up to date so no one has to re-explain the story. Free, and only the people you invite can ever see it.

Start a care circle →

Source Guidelines

NCCN Guidelines for Patients: Ovarian Cancer (2026)Browse all NCCN Guidelines for Patients →

Related Services

Services that may help with treatment for Ovarian Cancer patients

Cancer Commons

Treatment Options, Repository, Treatment Strategy, Personal

Tempus

Diagnostics, Treatment Options, Testing

CancerCare

Support & Advocacy, Community, Education, Treatment Strategy

Foundation Medicine